INM Pengajuan SEC - InMed Pharmaceuticals Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

LEI	549300VA5DNHEJGHG397
CIK	1728328

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to InMed Pharmaceuticals Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

August 5, 2025	424B3	InMed Pharmaceuticals Inc. 3,904,726 Common Shares Filed pursuant to Rule 424(b)(3) Registration Number 333-288594 PROSPECTUS InMed Pharmaceuticals Inc.
August 1, 2025	S-1/A	As filed with the Securities and Exchange Commission on July 31, 2025 As filed with the Securities and Exchange Commission on July 31, 2025 Registration No.
July 28, 2025	EX-99.1	InMed to Present INM-901 Data at Alzheimer’s Association International Conference (AAIC) 2025 Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed to Present INM-901 Data at Alzheimer’s Association International Conference (AAIC) 2025 ● Long-term INM-901 treatment in preclinical studies in advanced disease continues to show multi-modal activity Vancouver, British Columbia – July 28, 202
July 28, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2025 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commissi
July 9, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) InMed Pharmaceuticals Inc.
July 9, 2025	S-1	As filed with the Securities and Exchange Commission on July 9, 2025 As filed with the Securities and Exchange Commission on July 9, 2025 Registration No.
June 30, 2025	EX-4.2	Form of Preferred Investment Option (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed with the SEC on June 30, 2025). Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
June 30, 2025	EX-10.2	Form of Registration Rights Agreement Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of June 24, 2025, between InMed Pharmaceuticals Inc., a company incorporated under the laws of the Province of British Columbia (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This
June 30, 2025	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025 INMED PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (C
June 30, 2025	EX-10.3	Form of Existing Investment Option Amendment (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed with the SEC on June 30, 2025). Exhibit 10.3 June 24, 2025 Holder of Warrants to Purchase Common Shares issued on October 23, 2023 Re: Amendment to Existing Warrants Dear Holder: Reference is hereby made to the offering on or about the date hereof (the “Offering”) by InMed Pharmaceuticals Inc. (the “Company”) of its common shares, without par value (“Common Shares”), pre-funded warrants to purchase Common Shares and preferred in
June 30, 2025	EX-99.2	InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules Exhibit 99.2 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules Vancouver, British Columbia – June 26, 2025 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a pharmaceutical comp
June 30, 2025	EX-4.3	Form of Placement Agent Preferred Investment Option (incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed with the SEC on June 30, 2025). Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
June 30, 2025	EX-99.1	InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules Vancouver, British Columbia – June 25, 2025 – InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused
June 30, 2025	EX-4.1	Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on June 30, 2025). Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
June 30, 2025	EX-10.1	Form of Securities Purchase Agreement dated June 24, 2025 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on June 30, 2025). Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 24, 2025, between InMed Pharmaceuticals Inc., a company incorporated under the laws of the Province of British Columbia (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purc
June 24, 2025	EX-99.1	InMed’s INM-901 Significantly Reduces Neuroinflammation in Alzheimer’s Disease Ex Vivo Study Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed’s INM-901 Significantly Reduces Neuroinflammation in Alzheimer’s Disease Ex Vivo Study ● Demonstrates statistically significant reduction of pro-inflammatory cytokines, including IL-6, IL-1β, IL-2, and KC/Gro ● Significantly reduces levels of
June 24, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commissi
June 13, 2025	EX-10.1	Amendment to Standby Equity Purchase Agreement, dated June 13, 2025, by and between the Company and YA II PN, LTD (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on June 13, 2025). Exhibit 10.1 AMENDMENT TO STANDBY EQUITY PURCHASE AGREEMENT THIS AMENDMENT (the “Amendment”), dated as of June 13, 2025, to the Standby Equity Purchase Agreement (the “SEPA”), dated as of December 13, 2024, by and between YA II PN, LTD., a Cayman Islands exempt limited partnership (the “Investor”) and INMED PHARMACEUTICALS INC., a company organized under the laws of the Province of British Columbi
June 13, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 INMED PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commissi
June 13, 2025	EX-16.1	Letter from Marcum LLP, dated June 12, 2025, addressed to the Securities and Exchange Commission. Exhibit 16.1 June 12, 2025 Mr. Eric A. Adams InMed Pharmaceuticals Inc. 1445, 885 West Georgia St. Vancouver, B.C. Canada V6C 3E8 Re: InMed Pharmaceuticals Inc. Dear Mr. Adams: This is to confirm that the client-auditor relationship between InMed Pharmaceuticals Inc. (Commission File Number 0001728328) and Marcum llp has ceased effective June 12, 2025. Very truly yours, /s/ Marcum LLP Marcum LLP S
May 29, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
May 16, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
May 13, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 INMED PHARMACEUTICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commissio
May 13, 2025	EX-99.1	InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update Vancouver, British Columbia – May 12, 2025. InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused on developing a
May 12, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39685 INMED PHARMACEUTICAL
April 29, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
April 25, 2025	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2025 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commiss
April 25, 2025	EX-99.1	*REVISED* Filed via SEDAR+ Exhibit 99.1 April 25, 2025 *REVISED* Filed via SEDAR+ To All Applicable Exchanges and Securities Administrators Subject: InMed Pharmaceuticals Inc. (the “Issuer”) Notice of Meeting and Record Date Dear Sir/Madam: We are pleased to confirm the following information with respect to the Issuer’s upcoming meeting of securityholders: Meeting Type: Special Meeting Meeting Date: June 13, 2025 Record
April 8, 2025	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2025 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commissi
April 8, 2025	EX-99.1	Filed via SEDAR+ Exhibit 99.1 April 4, 2025 Filed via SEDAR+ To All Applicable Exchanges and Securities Administrators Subject: InMed Pharmaceuticals Inc. (the “Issuer”) Notice of Meeting and Record Date Dear Sir/Madam: We are pleased to confirm the following information with respect to the Issuer’s upcoming meeting of securityholders: Meeting Type: Special Meeting Meeting Date: June 13, 2025 Record Date for Notic
February 14, 2025	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2025 InMed Pharmaceuticals Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation
February 14, 2025	EX-99.2	InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update Exhibit 99.2 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update Vancouver, British Columbia – February 12, 2025. InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused on develo
February 14, 2025	EX-99.1	RESIGNATION Exhibit 99.1 RESIGNATION TO: lnMed Pharmaceuticals Inc. (the “Company”) Attention: Andrew Hull, Chairman Dear Andrew, I hereby tender my resignation for approval by the Company’s board of directors. Further, I hereby resign as a member of the Company’s Compensation Committee and Governance and Nomination Committee, effective immediately. DATED: December 18, 2024 /s/ Janet Grove JANET GROVE
February 13, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2025 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Comm
February 13, 2025	EX-99.1	InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update Vancouver, British Columbia – February 12, 2025. InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company“), a pharmaceutical company focused on develo
February 12, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39685 INMED PHARMACEUTI
February 3, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2025 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commi
February 3, 2025	EX-99.1	InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration ● INM-089 IVT formulation selected for continued development ● Demonstrated successful delivery at doses up to 10 times the projected therapeu
January 22, 2025	EX-99.1	InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds ● Marks the first jurisdictional issuance of an international patent for a family of novel small molecule compounds ● Patent covers novel analog compounds for therapeutic applic
January 22, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2025 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commi
January 21, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2025 INMED PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2025 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commi
January 21, 2025	EX-99.1	InMed’s INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer’s Disease Study Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed’s INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer’s Disease Study ● INM-901 significantly reduced pro-inflammatory cytokines associated with Alzheimer’s ● Statistically signif
January 2, 2025	424B3	3,000,000 Common Shares PROSPECTUS Filed pursuant to Rule 424(b)(3) Registration Number 333-284029 3,000,000 Common Shares This prospectus relates to the offer and resale by the selling shareholder identified herein, or the Selling Shareholder, or any of its pledgees, donees, assignees and successors-in-interest, or collectively, the permitted transferees, of up to 3,000,000 of our common shares, no par value per share, or the common shares.
December 30, 2024	S-1/A	As filed with the Securities and Exchange Commission on December 30, 2024 As filed with the Securities and Exchange Commission on December 30, 2024 Registration No.
December 30, 2024	CORRESP	INMED PHARMACEUTICALS INC. Suite 1445 – 885 West Georgia St. Vancouver, British Columbia, Canada V6C 3E8 INMED PHARMACEUTICALS INC. Suite 1445 – 885 West Georgia St. Vancouver, British Columbia, Canada V6C 3E8 VIA EDGAR December 30, 2024 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: InMed Pharmaceuticals Inc. Acceleration Request for Registration Statement on Form S-1 Filed December 23, 2024 (as amended by Pre-Effective Am
December 23, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) InMed Pharmaceuticals Inc.
December 23, 2024	S-1	As filed with the Securities and Exchange Commission on December 23, 2024 As filed with the Securities and Exchange Commission on December 23, 2024 Registration No.
December 20, 2024	EX-FILING FEES	Calculation of Filing Fee Tables Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) InMed Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common shares, no
December 20, 2024	S-8	As filed with the Securities and Exchange Commission on December 19, 2024 As filed with the Securities and Exchange Commission on December 19, 2024 Registration No.
December 19, 2024	EX-99.1	InMed Announces Results of 2024 Annual General Meeting EX-99.1 2 ea022531101ex99-1inmed.htm PRESS RELEASE, DATED DECEMBER 18, 2024 Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Announces Results of 2024 Annual General Meeting Vancouver, British Columbia – December 18, 2024. InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”),
December 19, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2024 InMed Pharmaceuticals Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation
December 18, 2024	EX-10.1	Standby Equity Purchase Agreement, dated December 13, 2024, by and between the Company and YA II PN, LTD (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on December 18, 2024). Exhibit 10.1 STANDBY EQUITY PURCHASE AGREEMENT THIS STANDBY EQUITY PURCHASE AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) dated as of December 13, 2024, is made by and between YA II PN, LTD., a Cayman Islands exempt limited company (the “Investor”), and INMED PHARMACEUTICALS INC., a company organized under the laws of British Columbia, Can
December 18, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2024 INMED PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Comm
December 18, 2024	EX-99.1	InMed Enters Into Standby Equity Purchase Agreement Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Enters Into Standby Equity Purchase Agreement Vancouver, British Columbia – December 17, 2024. InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused on developing a pipeline of proprietary small
November 20, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Comm
November 20, 2024	EX-99.1	InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System ● Cannabinol modulates distinct endocannabinoid system elements and exerts anti-inflammatory effects ● Supports therapeutic potential of cannabinol fo
November 15, 2024	EX-99.1	InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update Vancouver, British Columbia – November 14, 2024. InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused on develop
November 15, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Comm
November 14, 2024	SC 13G/A	INM / InMed Pharmaceuticals Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
November 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39685 INMED PHARMACEUT
November 12, 2024	EX-99.1	InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules Exhibit 99.1 NASDAQ: INM Suite 1445-885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules Vancouver, BC – November 8, 2024 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a pharmaceutical company focused on developing a pipeline of proprietary
November 12, 2024	8-K	Regulation FD Disclosure, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commi
November 12, 2024	SC 13G	INM / InMed Pharmaceuticals Inc. / AdvisorShares Trust Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) InMed Pharmaceuticals, Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 457637601 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of the Statement) Check the appropriate box to designate the rule pursu
November 5, 2024	8-K	Regulation FD Disclosure, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commi
November 5, 2024	EX-99.1	InMed Pharmaceuticals Announces Decision by Nasdaq Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy Nasdaq Listing Rules Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Announces Decision by Nasdaq Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy Nasdaq Listing Rules Vancouver, British Columbia – November 5, 2024. InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed”
October 28, 2024	EX-99.1	InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer’s Disease Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer’s Disease Vancouver, British Columbia–October 28, 2024 (InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or
October 28, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
October 28, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2024 INMED PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commi
October 28, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
October 24, 2024	EX-99.1	InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer’s Disease Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer’s Disease Vancouver, BC – October 24, 2024 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a pharmaceutical company focused on developing a pipe
October 24, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commi
October 23, 2024	EX-99.1	InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board Vancouver, BC – October 22, 2024 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a pharmaceutical company focus
October 23, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commi
October 17, 2024	424B3	InMed Pharmaceuticals Inc. Up to $875,546 Common Shares Filed Pursuant to Rule 424(b)(3) Registration No. 333-262532 PROSPECTUS SUPPLEMENT (To Prospectus dated February 4, 2022, as supplemented) InMed Pharmaceuticals Inc. Up to $875,546 Common Shares We have entered into an At The Market Offering Agreement, or the sales agreement, with H.C. Wainwright & Co., LLC, or Wainwright, dated April 7, 2022, as amended by that certain amendment dated June 27, 20
September 30, 2024	EX-10.19	Consulting Agreement, dated as of May 17, 2024, between the Company and Alexandra D. J. Mancini, d.b.a True North Synergy Inc. (incorporated by reference to Exhibit 10.19 to the Company’s Annual Report on Form 10-K filed with the SEC on September 30, 2024). Exhibit 10.19 CONSULTING AGREEMENT THIS AGREEMENT made as of the 17th day of May, 2024 with an effective date of 1st day of July, 2024 (the “Effective Date”). BETWEEN: InMed Pharmaceuticals Inc., a corporation registered in the Province of British Columbia and having its principal place of business at 310-815 W. Hastings St., Vancouver, BC, V6C 1B4, (the “Company”) AND: ALEXANDRA D. J. MANCINI, d.
September 30, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 INMED PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Com
September 30, 2024	EX-99.1	InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update Exhibit 99.1 NASDAQ: INM InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update ● Advances INM-901 program targeting several biological pathways associated with Alzheimer’s disease ● Further develops INM-089 demonstrating neuroprotection in the treatment of dry Age-related Macular Degeneration ● $4.6M revenues in fiscal year 2024, representing a 11% incr
September 30, 2024	EX-10.20	Scientific Advisory Board Consulting Agreement, dated as of September 4, 2024, between the Company and Barry Greenberg, Ph.D. (incorporated by reference to Exhibit 10.20 to the Company’s Annual Report on Form 10-K filed with the SEC on September 30, 2024). Exhibit 10.20 SCIENTIFIC ADVISORY BOARD CONSULTING AGREEMENT THIS AGREEMENT (this “Agreement”) dated for reference the 4th day of September 2024, (the “Effective Date”) BETWEEN: INMED PHARMACEUTICALS INC., a company incorporated under the laws of British Columbia having an office at Suite 1445, 885 W. Georgia Street, Vancouver, British Columbia, Canada V6C 3E8 (“InMed”) AND: Barry Greenberg, PhD,
September 30, 2024	EX-97.1	Compensation Clawback Policy Exhibit 97.1 InMed Pharmaceuticals Inc. EXECUTIVE COMPENSATION CLAWBACK POLICY Introduction The Board of Directors (the “Board”) of InMed Pharmaceuticals Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation ph
September 30, 2024	EX-21.1	Subsidiaries of the Company (incorporated by reference to Exhibit 21.1 of the Company’s Annual Report on Form 10-K filed with the SEC on September 30, 2024). Exhibit 21.1 SUBSIDIARIES OF INMED PHARMACEUTICALS INC. Subsidiary Jurisdiction Biogen Sciences Inc. BC Sweetnam Consulting Inc. BC InMed Pharmaceuticals Ltd. Delaware BayMedica, LLC Delaware
September 30, 2024	EX-4.13	Description of Securities of InMed Pharmaceuticals Inc. Exhibit 4.13 Description of Registrant’s Securities Registered under Section 12 of the Securities Exchange Act of 1934 The following description (this “Description”) of our Common Shares is a summary and does not purport to be complete. It is subject to, and qualified in its entirety by reference to, our Amended and Restated Articles (our “Articles”), which has been filed with the Securities and E
September 30, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT T UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39685 INMED PHARMACEUTIC
September 26, 2024	EX-99.1	Filed via SEDAR+ Exhibit 99.1 September 26, 2024 Filed via SEDAR+ To All Applicable Exchanges and Securities Administrators Subject: InMed Pharmaceuticals Inc. (the “Issuer”) Notice of Meeting and Record Date Dear Sir/Madam: We are pleased to confirm the following information with respect to the Issuer’s upcoming meeting of securityholders: Meeting Type: Annual General Meeting Meeting Date: December 18, 2024 Recor
September 26, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2024 INMED PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Com
September 20, 2024	EX-99.1	InMed Receives Nasdaq Delisting Notice, and Confirms it has Filed an Appeal and Obtained a Panel Hearing Date Exhibit 99.1 NASDAQ: INM Suite 1445-885 W. Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Receives Nasdaq Delisting Notice, and Confirms it has Filed an Appeal and Obtained a Panel Hearing Date Vancouver, BC – September 20, 2024 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a pharmaceutical company focus
September 20, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2024 INMED PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Com
August 21, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commis
August 21, 2024	EX-99.1	InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. Patents Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. Patents ● InMed’s intellectual property portfolio totals 13 patent families covering new chemical entities, formulations, manufacturing methods and methods of use Vancou
August 20, 2024	EX-99.1	InMed Pharmaceuticals Demonstrates INM-901 as an Oral Formulation Targeting Alzheimer’s Disease Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Demonstrates INM-901 as an Oral Formulation Targeting Alzheimer’s Disease ● High bioavailability of INM-901 oral formulation provides similar drug concentration levels in the brain as intraperitoneal (IP) injection Vancouver
August 20, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2024 INMED PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commis
July 30, 2024	EX-99.1	InMed Pharmaceuticals Announces Favorable Behavioral Outcomes with INM-901 in Long-Term Preclinical Alzheimer’s Disease Study, Confirming Previous Short-Term Pilot Study Data Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Announces Favorable Behavioral Outcomes with INM-901 in Long-Term Preclinical Alzheimer’s Disease Study, Confirming Previous Short-Term Pilot Study Data ● Results confirm improvements in cognitive function, memory and locomo
July 30, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2024 INMED PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commissi
June 28, 2024	EX-10.1	Amendment No. 1, dated June 27, 2024, to the At the Market Offering Agreement dated April 7, 2022 by and between InMed Pharmaceuticals Inc., and H.C. Wainwright & Co., LLC (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on June 28, 2024). Exhibit 10.1 June 27, 2024 InMed Pharmaceuticals Inc. Suite 310 – 815 W. Hastings Street Vancouver, British Columbia V6C 1B4 Attention: Eric A. Adams, President and Chief Executive Officer Dear Mr. Adams: Reference is made to the At The Market Offering Agreement, dated as of April 7, 2022 (the “ATM Agreement”), between InMed Pharmaceuticals Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wai
June 28, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2024 INMED PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (C
June 28, 2024	424B3	InMed Pharmaceuticals Inc. Up to $1,030,190 Common Shares Filed Pursuant to Rule 424(b)(3) Registration No. 333-262532 PROSPECTUS SUPPLEMENT (To Prospectus dated February 4, 2022, as supplemented) InMed Pharmaceuticals Inc. Up to $1,030,190 Common Shares We have entered into an At The Market Offering Agreement, or the sales agreement, with H.C. Wainwright & Co., LLC, or Wainwright, dated April 7, 2022, as amended by that certain amendment dated June 27,
June 11, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commissi
June 11, 2024	EX-99.1	InMed to Present at the Emerging Growth Conference Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed to Present at the Emerging Growth Conference Vancouver, BC – June 10, 2024 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small
May 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39685 INMED PHARMACEUTICAL
May 14, 2024	EX-99.1	InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update ● Reported positive preclinical data in both its Alzheimer’s and dry AMD programs ● Closed Fiscal Q3 with cash position of US$7.9 million Vanco
May 14, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commissio
May 14, 2024	EX-10.1	Scientific Advisory Board Consulting Agreement, dated as of April 12, 2024, between InMed Pharmaceuticals Inc. and David G. Morgan. Exhibit 10.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer’s Expert, to the Company’s Scientific Advisory Board Vancouver, BC – April 18, 2024 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, deve
April 18, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commiss
April 18, 2024	EX-99.1	InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer’s Expert, to the Company’s Scientific Advisory Board Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer’s Expert, to the Company’s Scientific Advisory Board Vancouver, BC – April 18, 2024 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, deve
April 16, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commiss
April 16, 2024	EX-99.1	InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration ● Small molecule drug acting as a preferential signaling ligand for CB1/CB2 ● Delivers improved retinal pigment epithelium integrity, neuroprotection and ph
April 5, 2024	EX-99.1	InMed’s INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer’s Disease Studies Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed’s INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer’s Disease Studies ● INM-901 receptor binding studies indicate preferential signaling agonism for CB1/CB2 and impacts the PPAR signaling
April 5, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2024 INMED PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commissi
March 20, 2024	8-K	Regulation FD Disclosure, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commiss
March 20, 2024	EX-99.1	InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance Vancouver, BC – March 20, 2024 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing, development and commercialization of rar
February 14, 2024	SC 13G/A	INMED PHARMACEUTICALS INC / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-inm123123a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* INMED PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 457637601 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appro
February 14, 2024	EX-99.1	InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update ● Advancing two new preclinical programs in Alzheimer’s and Age-Related Macular Degeneration ● Closed calendar year 2023 with cash position of US$9.5 million
February 14, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Comm
February 13, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39685 INMED PHARMACEUTI
February 9, 2024	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commi
February 9, 2024	EX-10.1	Employment Agreement by and between the Company and Narinder Netta “Neeta” Jagpal, effective February 20, 2024 Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT THIS AGREEMENT made this 20th day of February, 2024 (the “Effective Date”) BETWEEN: INMED PHARMACEUTICALS INC., a company incorporated under the laws of British Columbia with offices at Suite 310, 815 West Hastings St., Vancouver, B.C., V6C 1B4 (the “Company”) AND: Narinder Netta “Neeta” Jagpal (the “Executive”), of 14280 90A Ave., Surrey, BC V3V 7X9 (ea
February 9, 2024	EX-99.1	InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer Vancouver, BC – February 9, 2024 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the ma
January 19, 2024	EX-99.1	InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET Vancouver, BC – January 18, 2024 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq:
January 19, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2024 INMED PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commi
January 16, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2024 INMED PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commi
January 16, 2024	EX-99.1	InMed Pharmaceuticals Provides Business Update and Milestones for 2024 Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Provides Business Update and Milestones for 2024 ● Advancing INM-901 as a multimodal treatment option for Alzheimer’s Disease ● Advancing INM-089 in the treatment of Age-related Macular Degeneration ● Actively seeking partne
December 22, 2023	S-8	As filed with the Securities and Exchange Commission on December 21, 2023 As filed with the Securities and Exchange Commission on December 21, 2023 Registration No.
December 22, 2023	EX-FILING FEES	Calculation of Filing Fee Tables Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) InMed Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common shares, no
December 21, 2023	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 ☐ TRANSITI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-3968
December 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2023 InMed Pharmaceu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2023 InMed Pharmaceuticals Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation
December 20, 2023	EX-99.1	InMed Announces Results of 2023 Annual General Meeting Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Announces Results of 2023 Annual General Meeting Vancouver, BC – December 19, 2023 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabi
November 29, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2023 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Comm
November 29, 2023	EX-99.1	InMed Expands its Pharmaceutical Pipeline with INM-089 Targeting the Treatment of Age-Related Macular Degeneration Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Expands its Pharmaceutical Pipeline with INM-089 Targeting the Treatment of Age-Related Macular Degeneration ● INM-089 improves retinal function in in vivo preclinical AMD disease model ● Establishes cannabinol (CBN) analog candidate in a n
November 14, 2023	EX-4.13	Description of Securities of InMed Pharmaceuticals Inc. Exhibit 4.13 Description of Registrant’s Securities Registered under Section 12 of the Securities Exchange Act of 1934 The following description (this “Description”) of our common shares is a summary and does not purport to be complete. It is subject to, and qualified in its entirety by reference to, our Amended and Restated Articles (our “Articles”), which has been filed with the Securities and E
November 14, 2023	EX-99.1	InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update Vancouver, BC – November 14, 2023 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development,
November 14, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39685 INMED PHARMACEUT
November 14, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Comm
November 13, 2023	424B3	12,569,564 Common Shares InMed Pharmaceuticals Inc. Filed pursuant to Rule 424(b)(3) Registration Number 333-275410 PROSPECTUS 12,569,564 Common Shares InMed Pharmaceuticals Inc.
November 9, 2023	CORRESP	INMED PHARMACEUTICALS INC. Suite 310 - 815 West Hastings Street Vancouver, British Columbia, Canada V6C 1B4 INMED PHARMACEUTICALS INC. Suite 310 - 815 West Hastings Street Vancouver, British Columbia, Canada V6C 1B4 VIA EDGAR November 9, 2023 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: InMed Pharmaceuticals Inc. Acceleration Request for Registration Statement on Form S-1 Filed November 8, 2023 File No. 333-275410 Ladies and
November 8, 2023	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) InMed Pharmaceuticals Inc.
November 8, 2023	S-1	As filed with the Securities and Exchange Commission on November 8, 2023 As filed with the Securities and Exchange Commission on November 8, 2023 Registration No.
November 2, 2023	EX-99.1	InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023 Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023 Vancouver, BC – November 2, 2023 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutica
November 2, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commi
October 30, 2023	EX-99.1	InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules Vancouver, BC – October 24, 2023 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM)
October 30, 2023	EX-10.2	Registration Rights Agreement, dated November 17, 2022, between InMed Pharmaceuticals Inc. and the purchasers thereto (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on October 30, 2023). Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of October 24, 2023, between InMed Pharmaceuticals Inc., a company incorporated under the laws of the Province of British Columbia (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). T
October 30, 2023	EX-4.2	Form of Preferred Investment Option (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed with the SEC on October 30, 2023). Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
October 30, 2023	EX-10.1	Form of Securities Purchase Agreement dated October 24, 2023 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on October 30, 2023). Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 24, 2023, between InMed Pharmaceuticals Inc., a company incorporated under the laws of the Province of British Columbia (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “P
October 30, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2023 INMED PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2023 INMED PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation)
October 30, 2023	EX-4.3	Form of Placement Agent Preferred Investment Option (incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed with the SEC on October 30, 2023). Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
October 30, 2023	EX-10.3	Form of Inducement Letter dated October 24, 2023 (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed with the SEC on October 30, 2023). Exhibit 10.3 INMED PHARMACEUTICALS INC. October 24, 2023 Holder of Preferred Investment Options Issued in November 2022 Re: Inducement Offer to Exercise Preferred Investment Options Issued in November 2022 Dear Holder: InMed Pharmaceuticals Inc. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) the opportunity to receive (i) new preferred investment options to pur
October 30, 2023	EX-99.2	InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules Exhibit 99.2 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules Vancouver, BC – October 26, 2023 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”
October 30, 2023	EX-4.1	Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on October 30, 2023). Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
October 27, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
October 27, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
October 24, 2023	EX-99.1	InMed Pharmaceuticals Inc.’s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer’s Disease in Preclinical Proof-of-Concept Studies Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Inc.’s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer’s Disease in Preclinical Proof-of-Concept Studies ● In vitro Alzheimer’s disease studies show that INM-901 treated groups display neuroprotection and ex
October 24, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2023 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commi
September 29, 2023	EX-10.13	Consulting Agreement dated as of April 1, 2022, between InMed Pharmaceuticals Inc. and Brenda Edwards. Exhibit 10.13 CONSULTING AGREEMENT THIS AGREEMENT made as of the 1st day of April, 2022. BETWEEN: InMed Pharmaceuticals Inc., a corporation registered in the Province of British Columbia and having its principal place of business at 310-815 W. Hastings St., Vancouver, BC, V6C 1B4, (the “Company”) AND: Brenda Edwards, an individual having a residential address at 111-1232 Johnson Street, Coquitlam,
September 29, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2023 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Com
September 29, 2023	EX-4.13	Description of Securities of InMed Pharmaceuticals Inc. Exhibit 4.13 Description of Registrant’s Securities Registered under Section 12 of the Securities Exchange Act of 1934 The following description (this “Description”) of our common shares is a summary and does not purport to be complete. It is subject to, and qualified in its entirety by reference to, our Amended and Restated Articles (our “Articles”), which has been filed with the Securities and E
September 29, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT T UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39685 INMED PHARMACEUTIC
September 29, 2023	NT 10-K	SEC FILE NUMBER UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 001-39685 NOTIFICATION OF LATE FILING CUSIP NUMBER 457637601 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2023
September 29, 2023	EX-99.1	InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update ● Completed Phase 2 Clinical Trial demonstrating anti-itch activity of INM-755 (CBN) topical cream ● $4.1M revenues in fiscal year 2023, representi
September 29, 2023	EX-21.1	Subsidiaries of the Company. Exhibit 21.1 SUBSIDIARIES OF INMED PHARMACEUTICALS INC. Subsidiary Jurisdiction Biogen Sciences Inc. BC Sweetnam Consulting Inc. BC InMed Pharmaceuticals Ltd. Delaware BayMedica, LLC Delaware
September 25, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2023 INMED PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2023 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Com
September 25, 2023	EX-99.1	Filed via SEDAR Exhibit 99.1 September 25, 2023 Filed via SEDAR To All Applicable Exchanges and Securities Administrators Subject: InMed Pharmaceutical Inc. (the "Issuer") Notice of Meeting and Record Date Dear Sir/Madam: We are pleased to confirm the following information with respect to the Issuer's upcoming meeting of securityholders: Meeting Type: Annual General Meeting Meeting Date: December 19, 2023 Record
September 25, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2023 INMED PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2023 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Com
September 8, 2023	EX-99.1	InMed to Present at H.C. Wainwright 25th Annual Global Investment Conference Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed to Present at H.C. Wainwright 25th Annual Global Investment Conference Vancouver, BC – September 7, 2023 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development, manufactur
September 8, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2023 INMED PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2023 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Comm
July 24, 2023	EX-99.1	InMed to Participate in Fireside Chat with Water Tower Research on July 25, 2023 at 2pm ET Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed to Participate in Fireside Chat with Water Tower Research on July 25, 2023 at 2pm ET Vancouver, BC – July 21, 2023 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development,
July 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2023 INMED PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2023 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commissi
July 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2023 INMED PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2023 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commissi
July 20, 2023	EX-99.1	InMed Provides Update on BayMedica Rare Cannabinoid Business Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Provides Update on BayMedica Rare Cannabinoid Business ● $2.3M revenues (unaudited) in Q4 2023, representing 123% increase quarter over quarter (“QoQ”) ● Optimized and scaled up manufacturing processes over the last 12 months to meet increa
June 22, 2023	EX-99.1	InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa ● An exploratory clinical evaluation of the Phase 2 clinical trial data showed a positive indication of enhanced anti-itch activity for INM-755 ca
June 22, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2023 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commissi
June 1, 2023	EX-99.1	InMed’s Neurodegenerative Disease Study Presented at Canadian Neuroscience Meeting Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed’s Neurodegenerative Disease Study Presented at Canadian Neuroscience Meeting Vancouver, BC – June 1, 2023 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development, manufactu
June 1, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 INMED PHARMACEUTICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commissio
May 25, 2023	EX-99.1	InMed to Participate in Upcoming Virtual Investor Events Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed to Participate in Upcoming Virtual Investor Events Vancouver, BC – May 24, 2023 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization
May 25, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2023 INMED PHARMACEUTICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2023 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commissio
May 19, 2023	EX-99.1	InMed to Participate in Fireside Chat with Water Tower Research on May 23, 2023 at 1pm ET Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed to Participate in Fireside Chat with Water Tower Research on May 23, 2023 at 1pm ET Vancouver, BC – May 18, 2023 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development, ma
May 19, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2023 INMED PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2023 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commiss
May 16, 2023	EX-99.1	InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update · Completed enrollment in Phase 2 Clinical Trial; data readout expected during calendar 3Q 2023 · 120% quarter-over-quarter revenue growth in t
May 16, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 INMED PHARMACEUTICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commissio
May 15, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39685 INMED PHARMACEUTICAL
March 28, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2023 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commiss
March 28, 2023	EX-99.1	InMed Announces Conclusion of Patient Enrollment in Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Announces Conclusion of Patient Enrollment in Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa ● Marks the first time a Phase 2 trial has studied a cannabinol (CBN) formulation as a treatment option fo
March 14, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commiss
March 14, 2023	EX-99.1	InMed Announces Publication of Peer-Reviewed Study Showing the Anti-Inflammatory Potential of Rare Cannabinoids in Skin Conditions Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Announces Publication of Peer-Reviewed Study Showing the Anti-Inflammatory Potential of Rare Cannabinoids in Skin Conditions · Supports the therapeutic potential of rare cannabinoids in inflammatory skin conditions such as atopic dermatitis
March 7, 2023	EX-99.1	InMed to Participate in Upcoming Investor Events Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed to Participate in Upcoming Investor Events Vancouver, BC – March 6, 2023 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and
March 7, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2023 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commissi
February 21, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2023 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Comm
February 21, 2023	EX-99.1	InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update ● Closed calendar year 2022 with strong cash position of $11.5 million ● Approaches completion of enrollment for Ph 2 clinical trial in EB ● Advances research
February 17, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39685 INMED PHARMACEUTI
February 14, 2023	SC 13G	CA4576376012 / INMED PHARMACEUTICALS INC / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-inm123122.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* INMED PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 457637601 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate
February 10, 2023	NT 10-Q	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SEC FILE NUMBER 001-39685 SECURITIES AND EXCHANGE COMMISSION Washington, D.
January 10, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2023 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commi
January 10, 2023	EX-99.1	InMed Provides Business Update and Milestones for 2023 Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Provides Business Update and Milestones for 2023 ● Complete Phase 2 clinical trial enrollment in Epidermolysis Bullosa in 1Q 2023 ● Progress preclinical research in glaucoma in preparation for human trials ● Advance research using rare cann
December 16, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2022 InMed Pharmaceuticals Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation
December 16, 2022	EX-99.1	InMed Announces Results of 2022 Annual General Meeting Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Announces Results of 2022 Annual General Meeting Vancouver, BC ? December 15, 2022 ? InMed Pharmaceuticals Inc. (?InMed? or the ?Company?) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabi
December 15, 2022	424B3	5,090,918 Common Shares InMed Pharmaceuticals Inc. 424B3 1 ea170251-424b3inmedpharma.htm PROSPECTUS Filed pursuant to Rule 424(b)(3) Registration Number 333-268700 PROSPECTUS 5,090,918 Common Shares InMed Pharmaceuticals Inc. This prospectus relates to the offer and resale by the selling shareholders identified herein, or the Selling Shareholders, or any of their pledgees, donees, assignees and successors-in-interest, or collectively, the permitte
December 13, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2022 INMED PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2022 INMED PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation)
December 13, 2022	EX-10.1	Letter Agreement dated December 12, 2022 with Brio Financial Group Exhibit 10.1 100 Somerset Corporate Blvd 2nd Floor Bridgewater Township, New Jersey 08807 December 12, 2022 InMed Pharmaceuticals Inc Suite 310-815 W. Hastings Street Vancouver, B.C. Canada V6C 1B4 ATTN: Mr. Eric A. Adams, Chief Executive Officer In order to document the understanding between as to the scope of the work that Brio Financial Group will perform, as well as certain other matters, we a
December 13, 2022	EX-99.1	InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor Vancouver, BC ? December 12, 2022 ? InMed Pharmaceuticals Inc. (?InMed? or the ?Company?) (Nasdaq: INM), a leader in the pharmaceutical research, development and
December 13, 2022	EX-99.1	InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor Vancouver, BC ? December 12, 2022 ? InMed Pharmaceuticals Inc. (?InMed? or the ?Company?) (Nasdaq: INM), a leader in the pharmaceutical research, development and
December 13, 2022	EX-16.1	Letter from KPMG LLP dated December 12, 2022 Exhibit 16.1 KPMG LLP PO Box 10426 777 Dunsmuir Street Vancouver BC V7Y 1K3 Canada Telephone (604) 691-3000 Fax (604) 691-3031 December 12, 2022 Securities and Exchange Commission Washington, D.C. 20549 Ladies and Gentlemen: We were previously principal accountants for InMed Pharmaceuticals Inc. (the Company), and, under the date of September 23, 2022, we reported on the consolidated financial sta
December 13, 2022	EX-10.2	Consulting Agreement dated December 12, 2022 with Jonathan Tegge Exhibit 10.2 CONSULTING AGREEMENT THIS AGREEMENT made as of the 12th day of December, 2022. BETWEEN: INMED PHARMACEUTICALS INC., a corporation registered in the Province of British Columbia and having its principal place of business at 310-815 W. Hastings St., Vancouver, BC, V6C 1B4, Canada, (the ?Company?) AND: BRIO FINANCIAL GROUP, a corporation incorporated under the laws of USA, having an offi
December 13, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2022 INMED PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation
December 13, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2022 INMED PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation
December 12, 2022	CORRESP	INMED PHARMACEUTICALS INC. Suite 310 - 815 West Hastings Street Vancouver, British Columbia, Canada V6C 1B4 CORRESP 1 filename1.htm INMED PHARMACEUTICALS INC. Suite 310 - 815 West Hastings Street Vancouver, British Columbia, Canada V6C 1B4 VIA EDGAR December 12, 2022 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: InMed Pharmaceuticals Inc. Acceleration Request for Registration Statement on Form S-1 Filed December 7, 2022 File
December 7, 2022	S-1	As filed with the Securities and Exchange Commission on December 7, 2022 As filed with the Securities and Exchange Commission on December 7, 2022 Registration No.
December 7, 2022	EX-10.15	Amended and Restated Executive Employment Agreement, dated March 1, 2021, between Sarah Li and InMed Pharmaceuticals Inc. Exhibit 10.15 EMPLOYMENT AGREEMENT THIS AGREEMENT made this 1st day of March, 2021 (the “Effective Date”) BETWEEN: INMED PHARMACEUTICALS INC., a company incorporated under the laws of British Columbia with offices at Suite 310, 815 West Hastings St., Vancouver, B.C., V6C 1B4 (the “Company”) AND: SARAH LI (the “Employee”), of 6957 Cunningham Court, Burnaby, V5E 0B1 BC (each a “Party” and together,
December 7, 2022	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) InMed Pharmaceuticals Inc.
November 22, 2022	EX-99.1	InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market Vancouver, BC – November 18, 2022 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturi
November 22, 2022	EX-4.2	Form of Preferred Investment Option (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed with the SEC on November 22, 2022). Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
November 22, 2022	EX-4.1	Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on November 22, 2022). Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
November 22, 2022	EX-10.1	Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 17, 2022, between InMed Pharmaceuticals Inc., a company incorporated under the laws of the Province of British Columbia (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “
November 22, 2022	EX-4.3	Form of Placement Agent Preferred Investment Option (incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed with the SEC on November 22, 2022). Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
November 22, 2022	EX-99.2	InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market Exhibit 99.2 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market Vancouver, BC – November 21, 2022 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research
November 22, 2022	EX-10.2	Registration Rights Agreement, dated November 17, 2022, between InMed Pharmaceuticals Inc. and the purchasers thereto (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on November 22, 2022). Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of November 17, 2022, between InMed Pharmaceuticals Inc., a company incorporated under the laws of the Province of British Columbia (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
November 22, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2022 INMED PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2022 INMED PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation
November 17, 2022	EX-99.1	InMed Provides Update on Management Changes Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Provides Update on Management Changes Vancouver, BC ? November 17, 2022 ? InMed Pharmaceuticals Inc. (?InMed? or the ?Company?) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and c
November 17, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2022 INMED PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2022 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Comm
November 17, 2022	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2022 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Comm
November 17, 2022	EX-99.1	InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada (“NSERC”) Alliance Grant Funding Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada (“NSERC”) Alliance Grant Funding ● Targeting neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkin
November 15, 2022	EX-99.1	InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update Vancouver, BC – November 11, 2022 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical researc
November 15, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2022 INMED PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2022 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Comm
November 14, 2022	EX-FILING FEES	Calculation of Filing Fee Tables Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) InMed Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common shares, n
November 14, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39685 INMED PHARMACEUT
November 14, 2022	S-8	As filed with the Securities and Exchange Commission on November 14, 2022 As filed with the Securities and Exchange Commission on November 14, 2022 Registration No.
October 28, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEF 14A 1 def14a0422inmedpharm.htm DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the C
October 28, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEFA14A 1 ea167719-defa14ainmed.htm DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for U
October 26, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2022 INMED PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2022 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commi
October 26, 2022	EX-99.1	InMed Pharmaceuticals Supports Epidermolysis Bullosa Awareness Week Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Supports Epidermolysis Bullosa Awareness Week Vancouver, BC – October 26, 2022 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development and manufacturing of rare cannabinoi
October 19, 2022	424B3	2,073,735 Common Shares InMed Pharmaceuticals Inc. Filed pursuant to Rule 424(b)(3) Registration Number 333-267831 PROSPECTUS 2,073,735 Common Shares InMed Pharmaceuticals Inc.
October 14, 2022	CORRESP	INMED PHARMACEUTICALS INC. Suite 310 - 815 West Hastings Street Vancouver, British Columbia, Canada V6C 1B4 CORRESP 1 filename1.htm INMED PHARMACEUTICALS INC. Suite 310 - 815 West Hastings Street Vancouver, British Columbia, Canada V6C 1B4 VIA EDGAR October 14, 2022 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: InMed Pharmaceuticals Inc. Acceleration Request for Registration Statement on Form S-1 Filed October 12, 2022 File N
October 12, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) InMed Pharmaceuticals Inc.
October 12, 2022	S-1	As filed with the Securities and Exchange Commission on October 11, 2022 As filed with the Securities and Exchange Commission on October 11, 2022 Registration No.
September 29, 2022	EX-99.1	510 Burrard St, 3rd Floor Exhibit 99.1 510 Burrard St, 3rd Floor Vancouver BC, V6C 3B9 www.computershare.com September 29, 2022 To: All Canadian Securities Regulatory Authorities NASDAQ Exchange Subject: INMED PHARMACEUTICALS INC. Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : Annual General Meeting Record Date for Notice of Meeting
September 29, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2022 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Com
September 28, 2022	EX-4.13	Description of Securities of InMed Pharmaceuticals Inc. Exhibit 4.13 Description of Registrant?s Securities Registered under Section 12 of the Securities Exchange Act of 1934 The following description (this ?Description?) of our common shares is a summary and does not purport to be complete. It is subject to, and qualified in its entirety by reference to, our Amended and Restated Articles (our ?Articles?), which has been filed with the Securities and E
September 28, 2022	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2022 ☐ TRANSITI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-3968
September 28, 2022	EX-10.13	Consulting Agreement dated as of April 1, 2022, between InMed Pharmaceuticals Inc. and Brenda Edwards (incorporated by reference to Exhibit 10.13 of the Company’s Amendment No. 1 to Annual Report on Form 10-K/A filed with the SEC on September 28, 2022). Exhibit 10.13 CONSULTING AGREEMENT THIS AGREEMENT made as of the 1st day of April, 2022. BETWEEN: InMed Pharmaceuticals Inc., a corporation registered in the Province of British Columbia and having its principal place of business at 310-815 W. Hastings St., Vancouver, BC, V6C 1B4, (the ?Company?) AND: Brenda Edwards, an individual having a residential address at 111-1232 Johnson Street, Coquitlam,
September 23, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT T UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39685 INMED PHARMACEUTIC
September 23, 2022	EX-99.1	InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update Vancouver, BC ? September 23, 2022 ? InMed Pharmaceuticals Inc. (?InMed? or the ?Company?) (Nasdaq: INM), a leader in the pharmaceutical research,
September 23, 2022	EX-21.1	Subsidiaries of the Company. Exhibit 21.1 SUBSIDIARIES OF INMED PHARMACEUTICALS INC. Subsidiary Jurisdiction Biogen Sciences Inc. BC Sweetnam Consulting Inc. BC InMed Pharmaceuticals Ltd. Delaware BayMedica, LLC Delaware
September 23, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2022 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Com
September 20, 2022	S-8 POS	As filed with the Securities and Exchange Commission on September 20, 2022 As filed with the Securities and Exchange Commission on September 20, 2022 Registration No.
September 20, 2022	EX-99.1	InMed Pharmaceuticals to Report Full Year Fiscal 2022 Financial Results and Business Update on September 23, 2022 Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals to Report Full Year Fiscal 2022 Financial Results and Business Update on September 23, 2022 Vancouver, BC ? September 19, 2022 ? InMed Pharmaceuticals Inc. (?InMed? or the ?Company?) (Nasdaq: INM), a leader in the research,
September 20, 2022	POS AM	As filed with the Securities and Exchange Commission on September 20, 2022 As filed with the Securities and Exchange Commission on September 20, 2022 Registration No.
September 20, 2022	POS AM	As filed with the Securities and Exchange Commission on September 20, 2022 POS AM 1 ea166037-posaminmedpharma.htm POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 As filed with the Securities and Exchange Commission on September 20, 2022 Registration No. 333-262533 Registration No. 333-264187 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-262533 FORM S-3 REGISTRATION STATEMENT NO
September 20, 2022	POS AM	As filed with the Securities and Exchange Commission on September 20, 2022 POS AM 1 ea166037-posaminmedpharma.htm POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 As filed with the Securities and Exchange Commission on September 20, 2022 Registration No. 333-262533 Registration No. 333-264187 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-262533 FORM S-3 REGISTRATION STATEMENT NO
September 20, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2022 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Com
September 20, 2022	POS AM	As filed with the Securities and Exchange Commission on September 20, 2022 As filed with the Securities and Exchange Commission on September 20, 2022 Registration No.
September 20, 2022	POS AM	As filed with the Securities and Exchange Commission on September 20, 2022 As filed with the Securities and Exchange Commission on September 20, 2022 Registration No.
September 20, 2022	S-8 POS	As filed with the Securities and Exchange Commission on September 20, 2022 S-8 POS 1 ea166038-s8posinmedpharma.htm POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 As filed with the Securities and Exchange Commission on September 20, 2022 Registration No. 333-253912 Registration No. 333-260323 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-253912 FORM S-8 REGISTRATION STATEMENT N
September 14, 2022	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2022 INMED PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation
September 14, 2022	EX-4.2	Form of Preferred Investment Option (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed with the SEC on September 14, 2022). Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

INM / InMed Pharmaceuticals Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)

Other Listings